Please Wait a Moment
X

Articles

01May

CTS Implements HLA Class I and II Testing on the Gemini

01 May, 2019 | Return|

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.

 

 

 

 

Related

Bio-Rad Geenius HIV 1/2 Implementation

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...

Read More >

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...

Read More >

Reminder- Health and Human Services (HHS) email notifications for WNV reactives

Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...

Read More >

MD Revised Headers on CTS forms

Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...

Read More >

Spotlight on CTS AABB Annual Meeting Abstract Posters

CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...

Read More >

CTS implements Ortho VIP Viral Marker Testing Platform

On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...

Read More >